These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 28703277)

  • 21. MicroRNAs as prognostic markers in ovarian cancer.
    Llauradó M; Majem B; Altadill T; Lanau L; Castellví J; Sánchez-Iglesias JL; Cabrera S; De la Torre J; Díaz-Feijoo B; Pérez-Benavente A; Colás E; Olivan M; Doll A; Alameda F; Matias-Guiu X; Moreno-Bueno G; Carey MS; Del Campo JM; Gil-Moreno A; Reventós J; Rigau M
    Mol Cell Endocrinol; 2014 Jun; 390(1-2):73-84. PubMed ID: 24747602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis.
    Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A
    Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients.
    Penyige A; Márton É; Soltész B; Szilágyi-Bónizs M; Póka R; Lukács J; Széles L; Nagy B
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
    Koutsaki M; Spandidos DA; Zaravinos A
    Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA expression and identification of putative miRNA targets in ovarian cancer.
    Dahiya N; Sherman-Baust CA; Wang TL; Davidson B; Shih IeM; Zhang Y; Wood W; Becker KG; Morin PJ
    PLoS One; 2008 Jun; 3(6):e2436. PubMed ID: 18560586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application in Gene Editing in Ovarian Cancer Therapy.
    Luo S; Wang Y; Tao Y; Li S; Wang Z; He W; Wang H; Wang N; Xu J; Song H
    Cancer Invest; 2022 Apr; 40(4):387-399. PubMed ID: 34758691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues.
    Chen JL; Chen F; Zhang TT; Liu NF
    Int J Mol Med; 2016 Jun; 37(6):1601-10. PubMed ID: 27081781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
    Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
    Wang X; Ivan M; Hawkins SM
    Gynecol Oncol; 2017 Nov; 147(2):481-487. PubMed ID: 28866430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. microRNA and the pathogenesis of ovarian cancer--a new horizon for molecular diagnostics and treatment?
    Kuhlmann JD; Rasch J; Wimberger P; Kasimir-Bauer S
    Clin Chem Lab Med; 2012 Jan; 50(4):601-15. PubMed ID: 22505556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. microRNAs as biomarkers of ovarian cancer.
    Zhang H; Lu B
    Expert Rev Anticancer Ther; 2020 May; 20(5):373-385. PubMed ID: 32326768
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.
    Logan M; Hawkins SM
    Clin Sci (Lond); 2015 Feb; 128(3):153-80. PubMed ID: 25294164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.
    Zou X; Zhao Y; Liang X; Wang H; Zhu Y; Shao Q
    Front Immunol; 2021; 12():641937. PubMed ID: 33868274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.
    Ma Y; Lu Y; Lu B
    Cancer Invest; 2016 Oct; 34(9):465-476. PubMed ID: 27673409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential.
    Asiaf A; Ahmad ST; Arjumand W; Zargar MA
    Methods Mol Biol; 2018; 1699():23-43. PubMed ID: 29086366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA replacement therapy in cancer.
    Mollaei H; Safaralizadeh R; Rostami Z
    J Cell Physiol; 2019 Aug; 234(8):12369-12384. PubMed ID: 30605237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
    Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
    Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.
    Aghayousefi R; Hosseiniyan Khatibi SM; Zununi Vahed S; Bastami M; Pirmoradi S; Teshnehlab M
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):325-341. PubMed ID: 36378340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.
    Dong P; Xiong Y; Watari H; Hanley SJ; Konno Y; Ihira K; Yamada T; Kudo M; Yue J; Sakuragi N
    J Exp Clin Cancer Res; 2016 Sep; 35(1):132. PubMed ID: 27596137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.